UCB licenses Antengene TCE: $1.1B deal enters autoimmune T‑cell engager race

UCB SA licensed global rights to Antengene’s preclinical CD19×CD3 bispecific T‑cell engager ATG‑201 in a transaction valued at up to $1.1 billion. Antengene will complete initial Phase 1 studies before transferring the program to UCB; the deal includes $80 million upfront and near‑term milestones with further clinical and commercial payments tied to development progress. The agreement positions UCB in the growing T‑cell engager field being explored for autoimmune and hematologic indications and reflects continued big‑pharma interest in bispecific modalities beyond oncology.